Compare Neurocrine Biosciences Inc (NBIX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Virgin Galactic Holdings, Inc. trades at $3.34 (market cap $488.94M). The key difference: Neurocrine Biosciences Inc is far larger — about 34.3× Virgin Galactic Holdings, Inc.'s market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | SPCE | |
|---|---|---|
Market Cap | $16.76B | $488.94M |
Sector | Health | Industrials |
52-Week High | $185.50 | $7.52 |
52-Week Low | $123.10 | $2.17 |
Enterprise Value | $16.78B | $588.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
SPCE trades at $3.10, up 5.8% in the last session, with a bullish technical signal from moving averages but an overbought RSI. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025, though it has beaten EPS estimates for the last three quarters. Cash flow remains negative, but the trend is improving, with net cash flow narrowing to -$35.17 million in 2025 from -$207 million in 2022. Recent news highlights sector volatility and an upcoming Q2 2026 earnings report on August 12, 2026.
The outlook is highly speculative, with substantial execution risks and cash burn offset by potential in the nascent space tourism market. Analyst consensus is mixed, with 29% buy ratings. Investors face high volatility and operational challenges, making it suitable only for risk-tolerant portfolios seeking long-term growth in a disruptive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
